Sycrest (asenapine) from Lundbeck is launched in the UK for treatment of moderate to severe manic eposodes associated with Bipolar Disorder in...
Sycrest (asenapine)from Lundbeck is launched in the UK for treatment of moderate to severe manic episodes associated with Bipolar Disorder...
EMA has approved the Marketing Authorization Application for Sycrest (asenapine) sublingual tablets from Merck Inc./MSD for the treatment of moderate...
Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.